MEIP stock forecast
Our latest prediction for MEI Pharma, Inc.'s stock price was made on the Dec. 19, 2019 when the stock price was at 1.80$.
In the short term (2weeks), MEIP's stock price should underperform the market by -3.35%. During that period the price should oscillate between -10.81% and +13.90%.
In the medium term (3months), MEIP's stock price should underperform the market by -21.54%. During that period the price should oscillate between -40.87% and +28.95%.Get email alerts
About MEI Pharma, Inc.
MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
At the moment the company generates 6M USD in revenues.
On its last earning announcement, the company reported a loss of -0.57$ per share.
The book value per share is 0.71$
Three months stock forecastDec. 19, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|